Clinical Trial Update: Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is recruiting to evaluate pembrolizumab with N-803, alone or with PD-L1 t-haNK cells, for resectable head and neck squamous cell carcinoma. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• N-803
• PD-L1 t-haNK cells

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage II Squamous Cell Carcinoma of the Head and Neck, Stage III Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: RECRUITING